Efficacy and tolerability after 24 weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfected subjects

Efficacy and tolerability of telaprevir, pegylated interferon and ribavirin combination was assessed in 32 cirrhotic genotype 1 hepatitis C (HCV)-HIV coinfected patients. Undetectability of HCV-RNA was observed in 23/32 (71.9%) patients after 24 weeks. Treatment failure was observed in 9/32 subjects...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2014-04, Vol.104, p.59-61
Main Authors: GENEBAT, Miguel, VERA, Francisco, MARINO, Ana, LLUCH, José F, MARTINEZ-PEREZ, María A, MARIN, Jorge, RUIZ-MATEOS, Ezequiel, LEAL, Manuel, HERNANDEZ-QUERO, José, DOMINGO, Pere, GUARDIOLA, José M, MARTINEZ-MADRID, Onofre, MARTINEZ, Lorena, GARCIA DE LA LLANA, Francisco, SANCHEZ-VILLEGAS, Jorge, ALVAREZ, Hortensia
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antiviral agents
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Biological and medical sciences
Coinfection - drug therapy
Drug Therapy, Combination
Female
Gastroenterology. Liver. Pancreas. Abdomen
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - pathology
Hepatitis C, Chronic - virology
HIV Infections - drug therapy
HIV Infections - pathology
HIV Infections - virology
Human viral diseases
Humans
Infectious diseases
Interferons - administration & dosage
Liver Cirrhosis - pathology
Liver. Biliary tract. Portal circulation. Exocrine pancreas
Male
Medical sciences
Middle Aged
Oligopeptides - administration & dosage
Other diseases. Semiology
Pharmacology. Drug treatments
Ribavirin - administration & dosage
Time Factors
Treatment Outcome
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Viral hepatitis
Viral Load
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Efficacy and tolerability of telaprevir, pegylated interferon and ribavirin combination was assessed in 32 cirrhotic genotype 1 hepatitis C (HCV)-HIV coinfected patients. Undetectability of HCV-RNA was observed in 23/32 (71.9%) patients after 24 weeks. Treatment failure was observed in 9/32 subjects: four of them (45.5%) failed triple therapy due to virological rebound, while 5 patients (55.5%) experienced drug-related side effects driving to treatment interruption. These data suggest that telaprevir-containing triple therapy should be considered for treatment of genotype 1 HCV in HIV coinfected patients with liver cirrhosis, although a close vigilance is required because of potential drug-related side effects.
ISSN:0166-3542
1872-9096
DOI:10.1016/j.antiviral.2014.01.019